Associations of Helicobacter pylori infection across the cardiometabolic and steatotic liver disease spectrum: an umbrella review with targeted reanalysis of selected source reviews

Background Whether H. pylori infection is associated with cardiometabolic and steatotic liver diseases remains uncertain. Methods We searched five information sources from inception to July 12, 2026, for systematic reviews with meta-analyses; no language restriction was applied during searching, but non-English reports were excluded at screening. For five ratio-measure outcomes, we reanalyzed study-level data from one selected source review per outcome with extractable data (searches ending 2016–2023), using restricted maximum-likelihood random-effects models with Hartung–Knapp adjustment, prediction intervals, bias diagnostics, Ioannidis credibility criteria (classes I, convincing, to IV, weak), and an exploratory GRADE-based certainty assessment. Sensitivity analyses addressed the model, unit of analysis, adjustment, and source-review choice. Results ROBIS rated 30 of 37 reviews at high risk of bias, and all had critically low confidence on AMSTAR 2, a tool designed for intervention reviews. H. pylori infection was associated with prevalent nonalcoholic fatty liver disease [NAFLD; odds ratio (OR): 1.28; 95% confidence interval (CI): 1.14–1.44], prevalent metabolic dysfunction-associated steatotic liver disease (MASLD; OR: 1.12; 95% CI: 1.02–1.22), diabetes of any type (OR: 1.27; 95% CI: 1.09–1.47; type 2 diabetes, 1.43), metabolic syndrome (source-defined ratio, 1.34; 95% CI: 1.16–1.54), and hypertension (OR: 1.35; 95% CI: 1.04–1.76). Prediction intervals included 1.0 for four outcomes, so effects in new settings could be null. Most estimates were crude or of uncertain adjustment status, and adjustment attenuated the NAFLD association (OR: 1.21). No outcome met class I. NAFLD met class II criteria under the conventional DerSimonian–Laird model but class III under the primary model, under which no outcome exceeded class III; estimates and classes also changed with newer source reviews. The liver syntheses shared most primary studies (corrected covered area, 65.6%), and the published insulin-resistance estimate could not be reproduced. Certainty was very low throughout, and eradication evidence was inconsistent. Conclusions Associations were modest, heterogeneous, and based largely on overlapping, inconsistently adjusted cross-sectional evidence; NAFLD's higher credibility class does not indicate a stronger or causal association. In our interpretation, current evidence does not support testing for or eradicating H. pylori solely for a metabolic indication. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261435859 , PROSPERO, identifier CRD420261435859.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-20
DOI
https://doi.org/10.3389/fmed.2026.1964694
Primary Topic
Helicobacter pylori-related gastroenterology studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Associations of Helicobacter pylori infection across the cardiometabolic and steatotic liver disease spectrum: an umbrella review with targeted reanalysis of selected source reviews

Yang Won Min, Hyosoon Yoo, Tae Jun Kim, Hyuk Lee
Frontiers in Medicine
Helicobacter pylori-related gastroenterology studies
article

Associations of Helicobacter pylori infection across the cardiometabolic and steatotic liver disease spectrum: an umbrella review with targeted reanalysis of selected source reviews

Yang Won Min, Hyosoon Yoo, Tae Jun Kim, Hyuk Lee
article en

Abstract

Background Whether H. pylori infection is associated with cardiometabolic and steatotic liver diseases remains uncertain. Methods We searched five information sources from inception to July 12, 2026, for systematic reviews with meta-analyses; no language restriction was applied during searching, but non-English reports were excluded at screening. For five ratio-measure outcomes, we reanalyzed study-level data from one selected source review per outcome with extractable data (searches ending 2016–2023), using restricted maximum-likelihood random-effects models with Hartung–Knapp adjustment, prediction intervals, bias diagnostics, Ioannidis credibility criteria (classes I, convincing, to IV, weak), and an exploratory GRADE-based certainty assessment. Sensitivity analyses addressed the model, unit of analysis, adjustment, and source-review choice. Results ROBIS rated 30 of 37 reviews at high risk of bias, and all had critically low confidence on AMSTAR 2, a tool designed for intervention reviews. H. pylori infection was associated with prevalent nonalcoholic fatty liver disease [NAFLD; odds ratio (OR): 1.28; 95% confidence interval (CI): 1.14–1.44], prevalent metabolic dysfunction-associated steatotic liver disease (MASLD; OR: 1.12; 95% CI: 1.02–1.22), diabetes of any type (OR: 1.27; 95% CI: 1.09–1.47; type 2 diabetes, 1.43), metabolic syndrome (source-defined ratio, 1.34; 95% CI: 1.16–1.54), and hypertension (OR: 1.35; 95% CI: 1.04–1.76). Prediction intervals included 1.0 for four outcomes, so effects in new settings could be null. Most estimates were crude or of uncertain adjustment status, and adjustment attenuated the NAFLD association (OR: 1.21). No outcome met class I. NAFLD met class II criteria under the conventional DerSimonian–Laird model but class III under the primary model, under which no outcome exceeded class III; estimates and classes also changed with newer source reviews. The liver syntheses shared most primary studies (corrected covered area, 65.6%), and the published insulin-resistance estimate could not be reproduced. Certainty was very low throughout, and eradication evidence was inconsistent. Conclusions Associations were modest, heterogeneous, and based largely on overlapping, inconsistently adjusted cross-sectional evidence; NAFLD's higher credibility class does not indicate a stronger or causal association. In our interpretation, current evidence does not support testing for or eradicating H. pylori solely for a metabolic indication. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261435859 , PROSPERO, identifier CRD420261435859.

Frontiers in MedicineVol. 13
Samsung Medical Center (KR), Hallym University Dongtan Sacred Heart Hospital (KR), Sungkyunkwan University (KR)
Good health and well-being
Helicobacter pylori-related gastroenterology studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon